MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases

CHARLESTON, S.C. and NEW YORK--()--The Medical University of South Carolina and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have entered into a translational research collaboration focused on fibrotic diseases, including scleroderma, renal fibrosis and idiopathic pulmonary fibrosis. The agreement includes studies designed to improve the mechanistic understanding of fibrosis, explore patient segmentation based on disease characteristics and/or biomarker approaches and predictors of disease progression.

“Bristol-Myers Squibb’s collaboration with MUSC further strengthens and advances our Discovery research efforts in fibrotic diseases, a strategic area of focus for the company,” said Carl Decicco, Ph.D., Head of Discovery, R&D, Bristol-Myers Squibb. “MUSC brings substantial expertise in translational research and drug discovery related to fibrotic diseases including access to patient derived disease tissue samples that will help us accelerate the application of scientific knowledge to potential new treatment approaches for patients.”

“This is an exciting opportunity with the potential to make a significant impact in fibrotic diseases and in patients’ lives with these debilitating diseases,” said Karen Lackey, MUSC Center for Therapeutic Discovery and Development executive director and pharmacy associate professor. “Our goal with translational research is to shorten the timeline in getting patients the medications and treatments they need. We have unparalleled expertise in fibrosis research at MUSC, and this collaboration with a leader like Bristol-Myers Squibb in discovery and development of medications is going to take that foundational work to the next level.”

Bristol-Myers Squibb and MUSC are committed to addressing the unmet need in fibrotic diseases that are characterized by the formation of excess fibrous connective tissue in an organ or tissue, by identifying novel medicines to halt or slow disease progression. Among the assets in Bristol-Myers Squibb’s fibrosis portfolio are BMS-986020, a lysophosphatidic acid 1 (LPA1) receptor antagonist in Phase 2 development for the treatment of idiopathic pulmonary fibrosis (IPF), and a CCR2/5 dual antagonist in Phase 2 development for diabetic kidney disease. In addition, in November 2014, Bristol-Myers Squibb and Galecto Biotech AB announced an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of IPF and other pulmonary fibrotic conditions. Bristol-Myers Squibb and the California Institute for Biomedical Research (Calibr) also announced a worldwide research collaboration in January 2015 to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

About MUSC

Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $1.7 billion. MUSC operates a 750-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (one of 66 National Cancer Institute designated centers) Level I Trauma Center and Institute of Psychiatry. For more information on academic information or clinical services, visit www.musc.edu. For more information on hospital patient services, visit www.muschealth.org.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among other risks, there can be no guarantee that the investigational compounds discussed in this release will be successfully developed or approved for any of the indications described in this release. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2014 in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

Contacts

Bristol-Myers Squibb
Media:
Sarah Koenig, 609-252-4145, sarah.koenig@bms.com
Investors:
Ranya Dajani, 609-252-5330, ranya.dajani@bms.com
MUSC
Media:
Heather Woolwine, 843-792-7669, woolwinh@musc.edu

Release Summary

MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases

Contacts

Bristol-Myers Squibb
Media:
Sarah Koenig, 609-252-4145, sarah.koenig@bms.com
Investors:
Ranya Dajani, 609-252-5330, ranya.dajani@bms.com
MUSC
Media:
Heather Woolwine, 843-792-7669, woolwinh@musc.edu